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Abstract
Introduction The purpose of this study was to examine
whether the time horizon of time trade-off (TTO) and
standard gamble (SG) utility assessment influences utility
scores and discrimination between health states.
Methods In two phases, UK general population partici-
pants rated three osteoarthritis health states in TTO and SG
procedures with two time horizons: (1) 10-year and (2) a
time horizon derived from self-reported additional life
expectancy (ALE). The two time horizons were compared
in terms of mean utilities and discrimination among health
states.
Results In Phase 1, the 10-year tasks were completed by
80 participants, 35 of whom also completed utility
assessment with the ALE. In Phase 2, all 101 participants
completed procedures with both time horizons. Utility
scores tended to be lower with the ALE than the 10-year, a
difference that was statistically significant for two health
states with SG in Phase 1 (P\ 0.05), two health states with
TTO in Phase 2 (P\ 0.01), and one health state with SG in
Phase 2 (P\ 0.001). In Phase 1, rates of discrimination
between mild and moderate osteoarthritis health states
were significantly higher with the ALE than the 10-year
(TTO: P = 0.03; SG: P = 0.001). This pattern of dis-
crimination was similar in Phase 2.
Discussion Results suggest that the time horizon could
influence utility scores and discrimination among health
states. When designing utility evaluations, researchers
should carefully consider the time horizon so that the value
of health states is accurately represented in cost-utility
models.




The time trade-off (TTO) technique may be the most
common approach for obtaining health state utilities for use
in cost-utility analyses of medical treatments. The TTO
method involves a choice between living in a particular
health state for a given period of time or living in full
health for a shorter period of time [1, 2]. The amount of
time in full health is varied until the respondent is indif-
ferent between the two alternatives. Based on the point at
which the respondent is indifferent between the two alter-
natives, the health state is assigned a utility score, anchored
to values of 0 representing dead and 1 representing full
health.
Because the TTO procedure depends on perceptions of
time and life expectancy, the duration of time spent in the
health state is a key component of the task. This time
horizon varies across studies, and researchers must choose
a time horizon when designing a TTO utility assessment.
The most common TTO time horizon appears to be
10 years [3–10]. This time horizon was used in the influ-
ential Measurement and Valuation of Health (MVH) study,
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which identified utilities of EQ-5D health states in a rep-
resentative sample of the UK population [11, 12]. It is
likely that many researchers use this time horizon to
maximize consistency with the EQ-5D, which is the utility
assessment method preferred by the National Institute for
Health and Care Excellence (NICE) [13]. Although most
published TTO studies do not report justification for the
time horizon, some articles have stated that the 10-year
time horizon was selected to be consistent with the MVH
methods [14, 15].
A wide range of other TTO time horizons have also been
used [16], including 2 years [17, 18], 5 years [19, 20],
16 years [21], 20 years [22–25], 30 years [26–28],
36 years [29], and 50 years [30]. As an alternative
approach, some studies have used an additional life
expectancy (ALE) time horizon for each respondent,
depending on the respondent’s age and ALE [31–38]. In
contrast to the studies using a fixed time horizon for all
respondents, this ALE approach aims to present respon-
dents with realistic choices that correspond to reasonable
expectations for their own lifespan without introducing
bias that can stem from a fixed time horizon perceived as
either a gain or a loss [39].
Regardless of the TTO time horizon, the resulting utility is
interpreted on the same scale anchored to values of 0 repre-
senting dead and 1 representing full health, and utilities from
studies with different time horizons are generally considered
to be comparable when used in cost-utility models. However,
previous studies suggest that the time horizon may influence
the utility value [40]. Two of these studies found that patients
tend to trade a greater proportion of time when the TTO task
was conducted with a longer time horizon, resulting in lower
mean utility scores [41, 42]. However, because each respon-
dent rated only a single health state (i.e., his/her own), the
results do not illustrate the potential impact of TTO time
horizon on utility differences between multiple health states.
The distinction amongmultiple health states is a key outcome
of many health state utility studies, and these differences can
have a substantial impact on the results of a cost-utility model
that uses the utility scores.
Therefore, the primary purpose of the current study was
to examine whether the TTO time horizon influences the
resulting utility scores and discrimination among health
states. Respondents rated multiple hypothetical health
states (often called ‘‘vignettes’’) in TTO interviews with
two of the most commonly used time horizons: a 10-year
time horizon and an ALE time horizon derived from each
respondent’s self-reported additional life expectancy.
A secondary goal was to examine the influence of time
horizon on the results of standard gamble (SG) utility
assessment. SG is often referred to as the ‘‘classical’’ utility
valuation method because it is grounded in expected utility
theory [1, 43, 44]. When valuing health states with the SG
method, respondents are given a choice between certainty
(i.e., living in the health state being rated) and uncertainty.
The uncertain option is presented in the form of a gamble
between two possible outcomes including one that is more
preferable than the health state being rated (e.g., full
health) and another that is less preferable than the health
state being rated (e.g., dead). Because SG procedures focus
on probabilities as well as time, the choice of time horizon
might have a less direct impact on SG than on TTO. Still,
when completing an SG task, respondents are told how
much time will be spent in the health states, and this time
horizon could influence the results.
Methods
Overview of study design
This study was conducted in two phases. Phase 1 was con-
ducted as part of a larger study that included a one-on-one
utility interview in which all participants first rated three
health-state descriptions in TTO and SG tasks with a 10-year
time horizon. Then, participants were randomized to rate the
health states again in one of two variations of the TTO and
SG tasks. Half of the sample was randomized to a group that
performed the TTO and SG tasks again, but with an ALE
time horizon instead of the 10-year time horizon. The other
half performed a different task that was not included in the
current analysis. Therefore, in Phase 1, the sample for the
10-year time horizon was roughly twice as large as the sub-
group who completed the tasks with the ALE time horizon.
The results of Phase 1 suggested that the time horizon
may have an impact on results. Therefore, Phase 2 was
conducted to replicate the time horizon comparison and
examine whether a similar pattern of results emerged. All
participants rated the health states in TTO and SG tasks
with both the 10-year time and ALE time horizons. In
Phase 2, the order of TTO versus SG and the order of
10-year versus ALE were randomized.
Participants
The current study was conducted with general population
respondents in accordance with recommendations from
reimbursement agencies suggesting that utilities should
represent general population preferences [13, 45, 46].
Participants in both phases were required to be at least
18 years old, reside in the United Kingdom, and be able to
give written informed consent. Participants were not eli-
gible if they had cognitive impairment, hearing difficulty,
visual impairment, severe psychopathology, or insufficient
knowledge of English that could interfere with the ability
to complete study measures. Study inclusion criteria did
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not require any particular clinical characteristics. Phase 2
had two additional exclusion criteria: individuals were
excluded (1) if they participated in Phase 1; or (2) if their
self-reported ALE was less than 15 years.
Participants were recruited through newspaper and online
advertisements. For Phase 1, a total of 197 potential partic-
ipants responded to the newspaper advertisements, and 109
of these were reached for screening to assess whether they
met study inclusion criteria. Of the 109 screened partici-
pants, 2 were ineligible, 101 were scheduled for interviews,
and 81 attended interviews. Of the 81 participants, 1 was
unable to complete any of the utility procedures, while 2
others were unable to complete the SG. Therefore, the
sample includes 80 participants with TTO data and 78 with
SG data. Of the 80 participants, 39 were randomized to
perform the tasks with the ALE time horizon.
For Phase 2, a total of 274 potential participants
responded by telephone or email to the newspaper or online
advertisements, and 174 of these were reached for
screening. Of the 174 screened participants, 148 were eli-
gible, 141 were scheduled for interviews, and 108 attended
the interviews. All participants were rescreened at the time
of the interview, and 4 of the 108 participants were found
to be ineligible for the following reasons: unable to read
and write English, previously participated in Phase 1, self-
reported ALE less than 15 years, and unwilling to complete
the study demographic form. Three of the 104 eligible
participants were unable to complete the utility interview
procedures to provide valid TTO and SG data. Thus, a total
of 101 valid utility interviews were conducted. All analyses
were performed with the sample of participants who pro-
vided valid TTO and SG data (n = 101).
Health states
Three osteoarthritis health states associated with elective
total hip arthroplasty were presented during the utility
interview (see Appendix A for health state texts). These
health states were based on health states used in two pre-
vious studies describing patients with mild (health state A),
moderate (B), or severe (C) osteoarthrosis of the hip [47,
48], with minor edits made so that they would be appro-
priate for administration in the UK. These health states
were selected for use in the current study because they
were brief and easy to understand, with clear differences
among them.
Utility interview procedures and scoring
Individual interviews were conducted in London during
November 2011 (Phase 1) and May–June 2013 (Phase 2).
All procedures were approved by an independent Institu-
tional Review Board, and participants provided written
informed consent prior to completing any parts of the
study. The health states and procedures were presented
following a standardized interview script.
First, participants rated the health states using a visual ana-
logue scale (VAS) intended to introduce them to the health
states. Health states were presented on individual cards, and the
VAShad anchors of 0 (dead) and 100 (full health). Then, health
state utilitieswere obtained usingTTOandSGmethods [1, 43].
In Phase 1, the TTO and SG tasks were first administered with
the 10-year time horizon. The order of TTO and SG was ran-
domized. After completing the tasks with the 10-year time
horizon, half of the participants were randomized to complete
the taskswith theALE time horizon. In Phase 2, all participants
completed the TTO and SG tasks with both the 10-year and
ALE time horizons. The order of the time horizons and the
utility assessment method (i.e., TTO and SG) was randomized.
In the 10-year TTO task, participants were offered a
choice between spending 10 years in the health state being
rated versus spending varying shorter amounts of time in
full health, followed by death. Time was varied in 1-year
increments. The utility was calculated based on the choice
in which the respondent was indifferent between y years in
the health state being evaluated (i.e., 10 years) and x years
in full health (followed by y-x years dead). The resulting
utility (u) is calculated as u = x/y.
In the 10-year SG task, participants were offered a
choice between two alternatives, one that was certain and
one that was uncertain. Choice A was the uncertain choice
with two potential outcomes: either to remain in full health
for the 10-year period with a probability of P or death with
a probability of 1 - P. Choice B was to remain in the
health state being rated for 10 years. Probability P was
varied in 10 % increments until the participant was indif-
ferent between choices A and B, and the resulting utility is
equal to P at this point of indifference.
For the ALE time horizon, participants were first asked
how many additional years they expected to live. Then,
they completed the TTO and SG tasks with time horizons
of either 20, 30, 40, or 50 years, depending on which time
horizon corresponded most closely to their self-reported
additional life expectancy. Participants who reported an
additional life expectancy of less than 15 years did not
complete the tasks with the ALE time horizon because their
additional life expectancy did not differ substantially from
the 10-year time horizon.
Increments in the TTO task with the ALE time horizon
were proportional to those in the 10-year tasks described
above. For example, participants completing a TTO task
with a 40-year time horizon were presented with choices
varying by increments of 4 years. Because the SG choices
vary by percentages rather than years, the task with the
ALE time horizon was the same as the task with the
10-year time horizon, except participants were told that
The time horizon matters: results of an exploratory study varying the timeframe in time… 981
123
they would be living in the health states for a longer period
of time (i.e., 20–50 years, depending on self-reported
additional life expectancy).
Statistical analysis procedures
Continuous variables including utilities were summarized
in terms of means and standard deviations. Categorical
variables were summarized as frequencies and percentages.
Comparisons between two pairs of health states were
examined in the current analysis: A versus B and B versus
C. For each of these two pairs, mean utility values are
presented for all four utility assessment methods: 10-year
TTO, 10-year SG, TTO with the ALE time horizon, and SG
with the ALE time horizon. The primary questions of the
current study involved the extent to which the four methods
differed in terms of mean health state utilities and the
percentage of respondents who discriminated between
health state pairs. The frequency and percentage of
respondents who discriminated between each health state
pair is presented for each of the four methods. To examine
whether the rate of discrimination significantly differed
depending on the time horizon, follow-up Chi square
analyses were conducted for key comparisons.
Results
Sample description
The Phase 1 sample included 80 participants with a mean
age of 47.3 years (SD = 14.4) and were 48.8 % female
(Table 1). Most participants reported their ethnicity as
white (62.5 %). The majority of the sample was employed
either full time (25.0 %) or part time (35.0 %). The Phase 2
sample included 101 participants who had a mean age of
37.8 years (SD = 14.4) and were 49.5 % female (Table 1).
As in Phase 1, the majority of participants reported their
ethnic/racial background as white (60.4 %) and were
employed either full time (31.7 %) or part time (28.7 %).
In both phases, there were some respondents who reported
having arthritis [7 (8.8 %) of the 80 respondents in Phase 1;
2 (2.0 %) of the 101 respondents in Phase 2], which could
be similar to the condition described in the health states.
Self-reported ALE
At the beginning of the ALE time horizon task, participants
were asked to estimate their ALE. Their responses were
rounded to the nearest 10-year milestone so they could be
categorized into time horizon groups for the utility
assessment procedures (Table 2). In Phase 1, 39 partici-
pants were randomized to complete the utility tasks with
the ALE time horizon. Four (10.3 %) of these participants
reported additional life expectancy of less than 15 years,
which rounded to 10 years. Therefore, they were not asked
to complete utility assessments with the ALE time horizon.
The other 35 participants in Phase 1 reported that they
expected to live more than 14 additional years, and they
completed utility procedures with the ALE time horizon
that most closely matched their additional life expectancy.
As shown in Table 2, seven participants (17.9 %) reported
additional life expectancy within the range of 15–24 years,
and therefore completed the utility tasks with a 20-year
time horizon. Other participants were categorized in the
30-year group (n = 8; 20.5 %), 40-year group (n = 6;
15.4 %), or the 50-year group (n = 14; 35.9 %).
In Phase 2, potential participants were excluded from
the study if they expected to live fewer than 15 years. As in
Phase 1, participants were categorized into time horizon
groups that most closely matched their self-reported ALE.
Table 1 Demographic characteristics
Demographic characteristics Phase 1 Phase 2
Age (mean, SD) 47.3 (14.4) 37.8 (14.4)
Gender (n, %)
Male 41 (51.3 %) 51 (50.5 %)
Female 39 (48.8 %) 50 (49.5 %)
Ethnicity (n, %)
White 50 (62.5 %) 61 (60.4 %)
Black 13 (16.3 %) 12 (11.9 %)
Asian 8 (10.0 %) 20 (19.8 %)
Other 9 (11.3 %) 8 (7.9 %)
Marital status (n, %)
Single 37 (46.3 %) 67 (66.3 %)
Married/living with partner 23 (28.8 %) 22 (21.8 %)
Divorced/separated/widowed 20 (25.0 %) 12 (11.9 %)
Employment status (n, %)
Full-time work 20 (25.0 %) 32 (31.7 %)
Part-time work 28 (35.0 %) 29 (28.7 %)
Unemployed 11 (13.8 %) 12 (11.9 %)
Othera, b 21 (26.3 %) 28 (27.7 %)
Education level (n, %)
No university degreec, d 41 (51.3 %) 41 (40.6 %)
University or postgraduate degree 39 (48.8 %) 60 (59.4 %)
a Phase 1: Other employment includes homemaker (n = 3), student
(n = 2), retired (n = 15), and disabled (n = 1)
b Phase 2: Other employment includes homemaker (n = 2), student
(n = 15), retired (n = 8), disabled (n = 1), and other (n = 2)
c Phase 1: No university degree includes no formal qualifications
(n = 1), GCSE/O levels (n = 17), A levels (n = 10), and voca-
tional/work based qualifications (n = 13)
d Phase 2: No university degree includes no formal qualifications
(n = 3), GCSE/O levels (n = 12), A levels (n = 14), voca-
tional/work based qualifications (n = 11), and college (n = 1)
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The four time horizon groups were as follows: 20-year
(n = 13; 12.9 %), 30-year (n = 20; 19.8 %), 40-year
(n = 20; 19.8 %), and 50-year (n = 48; 47.5 %).
Mean utilities
Table 3 presents mean health state utilities in Phase 1 and
Phase 2. In Phase 1, health state A had a mean TTO utility
score of 0.85 with both the 10-year and ALE time horizons.
However, TTO utilities for health states B and C and SG
utilities for all three health states were consistently lower
with the ALE time horizon than with the 10-year time
horizon. These differences between the two time horizons
ranged from 0.03 to 0.09, and the difference was statisti-
cally significant for health states A and B in the standard
gamble (A: 0.86 versus 0.89; P = 0.02 and B: 0.76 versus
0.85; P = 0.0067).
In Phase 2, all health state utilities were lower with the
ALE time horizon than with the 10-year time horizon. The
utility difference between the two time horizons ranged
from 0.02 to 0.06 in the TTO, with a statistically significant
difference between time horizons for health states B and C
(B: 0.68 versus 0.74; P = 0.0019 and C: 0.33 versus 0.39;
P = 0.0047). In the SG, the utility difference between the
two time horizons ranged from 0.01 to 0.08, with a sta-
tistically significant difference between time horizons for
health state C (0.36 versus 0.44; P = 0.0002).
Differentiating between health states
A and B: Phase 1
With all assessment methods, health state A representing
mild osteoarthritis had a higher mean score than health state
B representing moderate osteoarthritis (Table 4). In Phase 1,
the mean difference between the two health states was 18 on
the VAS with a possible range of 0–100. Utility differences
between the two health states were 0.06 with the 10-year SG,
0.09 with the 10-year TTO, and 0.11 with the ALE time
horizons. Nearly all participants (97.5 %) rated health state
A higher than health state B on the VAS, indicating that
participants could distinguish between these two health
states, and there was a consistent preference for A over B.
However, the 10-year tasks did not detect this preference for
the majority of respondents. In the 10-year TTO task, only
32.5 %of respondents distinguished betweenA andB. In the
10-year SG task, only 23.1 % of respondents distinguished
between these two health states. In TTO and SG tasks with
the ALE time horizon, 54.3 % of participants differentiated
between health states A and B, suggesting that the ALE time
horizon resulted in greater discrimination between health
states than the 10-year time horizon.
Chi square analyses were conducted to examine whether
there was a statistically significant difference between the
10-year and ALE time horizons with regard to the frequency
of participants who differentiated between health states A
and B (Table 5). For the TTO methods, results of the 2 by 2
Chi square indicate that there was a significant difference
between the two time horizons in terms of health state dif-
ferentiation (v2 = 4.9; P = 0.03). Results followed the
same pattern for the SG methods (v2 = 10.7; P = 0.001).
Differentiating between health states
A and B: Phase 2
In Phase 2, the mean difference between health states A
and B was 24.8 with the VAS, 0.09 with the 10-year SG,
Table 2 Frequency of participants in additional life expectancy (ALE) categories
Life expectancy categoriesa ALE time horizon Respondent’s age ALE ? age
N Mean (SD) Minimum Maximum Mean (SD) Mean (SD)
Phase 1
0–14 years 4 (10.3 %) 10.3 (1.3) 9 12 60.5 (10.2) 70.8 (10.6)
15–24 years 7 (17.9 %) 19.6 (2.1) 15 22 59.7 (8.9) 79.3 (8.0)
25–34 years 8 (20.5 %) 29.3 (3.0) 25 34 47.5 (6.9) 76.8 (6.5)
35–44 years 6 (15.4 %) 39.8 (2.9) 35 44 37.3 (11.7) 77.2 (11.9)
45 years or more 14 (35.9 %) 55.6 (10.1) 45 80 31.9 (10.3) 87.4 (10.0)
Phase 2
15–24 years 13 (12.9 %) 18.8 (2.6) 15 23 54.2 (16.9) 73.1 (16.8)
25–34 years 20 (19.8 %) 28.9 (2.8) 25 34 49.4 (11.7) 78.3 (11.9)
35–44 years 20 (19.8 %) 38.7 (2.5) 35 43 39.1 (10.1) 77.7 (10.2)
45 years or more 48 (47.5 %) 57.5 (9.0) 45 80 27.9 (6.3) 85.4 (8.1)
a In Phase 1, this question was presented only to the subgroup of 39 respondents who were randomized to complete utility tasks with the ALE
time horizon. The 4 respondents in the 0–14 year category did not complete the ALE time horizon tasks because their self-reported ALE rounded
to 10 years. In Phase 2, all participants responded to this question
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Table 3 Mean utilities








t statistic P value
Phase 1
TTO
A (mild) 35 0.85 (0.14) 0.85 (0.14) -0.00 (0.14) -0.1 0.95
B (moderate) 34 0.76 (0.18) 0.74 (0.20) 0.03 (0.16) 1.0 0.34
C (severe) 26 0.50 (0.31) 0.46 (0.28) 0.06 (0.21) 1.5 0.15
SG
A (mild) 35 0.89 (0.13) 0.86 (0.13) 0.03 (0.07) 2.4 0.02
B (moderate) 34 0.85 (0.15) 0.76 (0.21) 0.09 (0.18) 2.9 0.0067
C (severe) 26 0.60 (0.35) 0.58 (0.33) 0.03 (0.23) 0.7 0.47
Phase 2
TTO
A (mild) 101 0.84 (0.14) 0.82 (0.16) 0.02 (0.15) 1.6 0.12
B (moderate) 101 0.74 (0.24) 0.68 (0.26) 0.05 (0.17) 3.2 0.0019
C (severe) 101 0.39 (0.45) 0.33 (0.48) 0.06 (0.19) 2.9 0.0047
SG
A (mild) 101 0.86 (0.15) 0.85 (0.15) 0.01 (0.15) 1.0 0.34
B (moderate) 101 0.77 (0.26) 0.75 (0.25) 0.02 (0.18) 1.4 0.17
C (severe) 101 0.44 (0.44) 0.36 (0.44) 0.08 (0.21) 3.8 0.0002
ALE additional life expectancy time horizon, SD standard deviation, SG standard gamble, TTO time trade-off
a N is the number of respondents who completed tasks with both time horizons for each health state. In Phase 1, N for health states B and C
varies because participants who rated a health state as negative (i.e., worse than dead) were not given a utility score. In Phase 2, if participants
indicated that a health state was worse than dead, they were offered a choice between immediate death (alternative 1) and a life span (alternative
2) beginning with varying amounts of time in the health state being rated, followed by full health. For these negative utilities, the current study
used a common scoring approach that limits the score range between 0 and -1 (formula: u = -x/t, where x is time in full health, and t is the total
life span of alternative 2 in the TTO choice) [1, 12, 43]
Table 4 Comparison between health states A (mild osteoarthritis) and B (moderate osteoarthritis)
Utility assessment method Na Mean utility values Difference between health
states A and B
Frequency and percentage of respondents
differentiating between health states
A and B (i.e., utility of A[ utility of B)A (mild) B (moderate)
Phase 1
VAS 80 75.20 57.18 18.03 78 (97.5 %)
TTO 10-year 80 0.88 0.79 0.09 26 (32.5 %)
TTO ALE 35 0.85 0.74 0.11 19 (54.3 %)
SG 10-year 78 0.91 0.86 0.06 18 (23.1 %)
SG ALE 35 0.86 0.76 0.11 19 (54.3 %)
Phase 2
VAS 101 75.93 51.14 24.79 101 (100.0 %)
TTO 10-year 101 0.84 0.74 0.11 52 (51.5 %)
TTO ALE 101 0.82 0.68 0.14 63 (62.4 %)
SG 10-year 101 0.86 0.77 0.09 35 (34.7 %)
SG ALE 101 0.85 0.75 0.10 46 (45.5 %)
ALE additional life expectancy time horizon, SG standard gamble, TTO time trade-off, VAS visual analog scale
a Number of respondents who participated in each utility assessment method
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0.11 with the 10-year TTO, 0.10 with the ALE SG, and
0.14 with the ALE TTO. In the 10-year TTO task, 51.5 %
of respondents distinguished between A and B, compared
with 62.4 % in the ALE TTO task. In the 10-year SG task,
34.7 % of respondents distinguished between these two
health states, compared with 45.5 % in the ALE SG task.
Although these rates of differentiation were numerically
higher with the ALE time horizon than the 10-year time
horizon, Chi square analyses did not find a significant
difference between the time horizons (v2 = 2.4; P = 0.12
for TTO and 2.5; P = 0.11 for SG).
Differentiating between health states B and C: Phase
1
With all assessment methods, health state B representing
moderate osteoarthritis had a higher mean score than health
state C representing severe osteoarthritis (Table 6). In
Phase 1, the mean difference between the two health states
was 27 on the VAS, 0.21 with both SG methods, 0.25 with
the 10-year TTO, and 0.31 with the ALE time horizon
TTO.
With all utility methods in Phase 1, the majority of
respondents differentiated between these two health states.
All but one of the 80 participants (98.8 %) rated health
state B higher than health state C on the VAS, and this
difference between the two health states was also reflected
in the TTO and SG utility tasks for most participants
(Table 6). Chi square analyses examining rates of differ-
entiation between B and C did not yield statistically sig-
nificant differences between the 10-year and ALE time
horizons (TTO: v2 = 1.0, P = 0.31; SG: v2 = 0.12,
P = 0.73). Although the difference between the two time
horizons was not statistically significant, the TTO with an
ALE time horizon did result in a slightly greater rate of
differentiation than the TTO with a 10-year time horizon
(85.7 versus 77.5 %).
Differentiating between health states B and C: Phase
2
In Phase 2, themean difference between the two health states
was 21 on the VAS, 0.35 with both TTO methods, 0.33 with
the 10-year SG, and 0.38 with the ALE time horizon SG.
With all utility methods, the majority of respondents dif-
ferentiated between these two health states. All participants
(100.0 %) rated health state B higher than health state C on
the VAS, and this difference between the two health states
was also reflected in the TTO and SG utility tasks for most
participants (Table 6). Although a slightly higher rate of
respondents differentiated between health states with the
ALE time horizon than the 10-year time horizon (91.1 versus
88.1 % with TTO; 90.1 versus 82.2 % with SG), Chi square
analyses did not find statistically significant differences
between the two time horizons (TTO: v2 = 0.48, P = 0.49;
SG: v2 = 2.65, P = 0.10).
Table 5 Health state A (mild osteoarthritis) versus health state B (moderate osteoarthritis): Chi square analysis comparing 10-year time horizon
to additional life expectancy (ALE) time horizon
Health state preferences (n, %) Time horizon in each utility task Chi square P value
10-year time horizon ALE time horizona
Phase 1
TTO
A[Bb 26 (32.5 %) 19 (54.3 %) 4.9 0.03
A = Bc 54 (67.5 %) 16 (45.7 %)
SG
A[Bb 18 (23.1 %) 19 (54.3 %) 10.7 0.001
A = Bc 60 (76.9 %) 16 (45.7 %)
Phase 2
TTO
A[Bb 52 (51.5 %) 63 (62.4 %) 2.4 0.12
A = Bc 49 (48.5 %) 38 (37.6 %)
SG
A[Bb 35 (34.7 %) 46 (45.5 %) 2.5 0.11
A = Bc 66 (65.3 %) 55 (54.5 %)
ALE additional life expectancy time horizon, SG standard gamble, TTO time trade-off
a The ALE time horizon was 20, 30, 40, or 50 years, depending on the self-reported additional life expectancy of each participant
b This row includes the frequency and percentage of participants who provided a greater utility value for health state A than for health state B
c This row includes the frequency and percentage of participants who provided the same utility value for health state A and health state B
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Discussion
Findings add to previous literature suggesting that the time
horizon of the utility assessment task could have an impact
on the results [10, 41, 42, 49]. In the current analyses
comparing the 10-year time horizon to the ALE time
horizon, two trends emerged. First, the longer time horizon
appears to lead to increased rates of discrimination among
health states, which has not been examined in previous
research. The difference between the two time horizons
emerged primarily in comparisons between health states A
(mild osteoarthritis) and B (moderate osteoarthritis).
Compared with the 10-year time horizon, the ALE
approach had a greater ability to detect and quantify
respondents’ preferences for health state A over health
state B. This finding highlights the importance of the time
horizon by showing that it may influence the extent to
which direct utility elicitation can distinguish among health
states. Essentially, TTO studies using the 10-year time
horizon to be consistent with the MVH study could fail to
detect some meaningful differences between health states.
When assessing utilities of multiple health states, it is
essential that the assessment method be able to detect
meaningful differences in preference. If one health state is
truly preferred over another, the resulting utilities must
reflect this distinction so that the difference between health
states can be represented accurately in a cost-utility analysis.
Distinctions among health state utilities have a direct impact
on the results of cost-utility models, and failure to detect true
differences in health state preference would limit the accu-
racy and usefulness of any model using the utilities. Because
healthcare policy and reimbursement decisions are often
directly informed by the results of cost-utility models,
accurate distinction between health states is critical.
The difference between the time horizons was not as pro-
nounced or consistent when examining discrimination between
health states B and C. The great majority of respondents had a
clear preference for B over C regardless of the utility assess-
ment method. It seems likely that the utility assessment
approach has less influence on discriminationwhen differences
between health states are more substantial because these dif-
ferences will be detected with almost any assessment method.
The second trend is that utility scores tended to be lower
with the ALE time horizon than with the 10-year time
horizon (Table 3). This result is consistent with previous
studies reporting that longer TTO time horizons yielded
more willingness to trade, resulting in lower utility scores,
among respondents rating their own health [41, 42]. The
current study adds to these previous results by demon-
strating that a longer TTO time horizon was associated
with lower utility scores when rating hypothetical health
states instead of one’s own health. In addition, while pre-
vious studies have focused on the TTO time horizon [40],
current results suggest that the time horizon may also
influence results in SG utility assessment.
It should be noted that the utility differences between
time horizons varied across the health states and methods.
The ALE time horizon resulted in lower utility scores than
the 10-year time horizon in 11 of the 12 comparisons
presented in Table 3, with the magnitude of mean differ-
ences ranging from 0.01 to 0.09. The magnitude of these
differences exceeded a suggested guideline for a clinically
important difference (at least 0.05) [50] in two of six
comparisons in Phase 1 and three of six in Phase 2.
Table 6 Comparison of responses between health states B (moderate osteoarthritis) and C (severe osteoarthritis)
Utility assessment method Na Mean utility values Difference between health
states B and C
Frequency and percentage of respondents
differentiating between health states B and C
(i.e., utility of B[ utility of C)B (moderate) C (severe)
Phase 1
VAS 80 57.18 30.92 26.59 79 (98.8 %)
TTO 10-year 80 0.79 0.59 0.25 62 (77.5 %)
TTO ALE 35 0.74 0.46 0.31 30 (85.7 %)
SG 10-year 78 0.86 0.68 0.21 56 (71.8 %)
SG ALE 35 0.76 0.58 0.21 24 (68.6 %)
Phase 2
VAS 101 51.14 30.11 21.03 101 (100.0 %)
TTO 10-year 101 0.74 0.39 0.35 89 (88.1 %)
TTO ALE 101 0.68 0.33 0.35 92 (91.1 %)
SG 10-year 101 0.77 0.44 0.33 83 (82.2 %)
SG ALE 101 0.75 0.36 0.38 91 (90.1 %)
ALE additional life expectancy time horizon, SG standard gamble, TTO time trade-off, VAS visual analog scale
a Number of respondents who participated in each utility assessment method
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Although this difference was small in some cases, small
differences between health states can often shift the out-
come of a cost-utility model, particularly when modeling a
large number of patients over a long timespan. Therefore,
the choice of time horizon in a valuation study could have a
substantial influence on the outcome of a model using the
resulting utility values as inputs.
Although this study was not designed to test the QALY
(i.e., quality-adjusted life year) model, results add to lit-
erature raising questions about the assumptions underlying
the QALY. One key assumption, often referred to as con-
stant proportional trade-off, is that ‘‘health state values
must be independent of the duration of states [1].’’ Current
results add to previous literature suggesting that duration
can affect one’s valuation of a health state, which violates
this assumption [40, 51].
The findings reported here should be interpreted with
caution because, despite consistent trends across the two
study phases, differences between the 10-year and ALE
time horizons were not always statistically significant. For
example, while the ALE time horizon was associated with
lower utility scores than the 10-year time horizon in 11 of
12 comparisons (Table 3), only 5 of these 11 were statis-
tically significant. In addition, although the ALE time
horizon had greater rates of discrimination between health
states A and B in both phases, this difference was only
statistically significant in Phase 1. Perhaps the inconsistent
statistical significance is related to the relatively small
sample size, which is a study limitation. This was an
exploratory study with limited resources designed to
identify potential methodological issues. It is possible that
the sample size did not offer sufficient statistical power to
detect differences in all analyses. Therefore, while the
current results generally support the hypothesis that the
time horizon has an impact on utility scores and discrimi-
nation among health states, future research with larger
samples is needed to provide confidence in this finding.
Another limitation is that this study was conducted with
a small number of health states. It is possible that the
impact of time horizon could be different for health states
representing different types of medical or psychiatric
conditions. Therefore, it is not known whether current
findings are generalizable to other health states. Future
research may examine the impact of time horizon across a
wider range of disease characteristics and symptom
severity.
Despite these limitations, given that the time horizon of
a utility task could influence the results, researchers should
carefully consider the advantages and disadvantages of
possible time horizons when designing a direct utility
elicitation study. The 10-year time horizon has two
advantages. First, it is consistent with the commonly cited
MVH valuation of EQ-5D health states, and a common
assumption is that utilities derived from a 10-year TTO
task may be comparable to EQ-5D utilities. Second, the
10-year time horizon simplifies interview procedures for
interviewers and respondents.
However, the 10-year time horizon may not always be
the most effective approach for identifying differences
among health state preferences, particularly for younger
respondents whose subjective ALE far exceeds 10 years
[10]. The ALE approach has the advantage of presenting
more realistic choices for each respondent. Because the
task is consistent with reasonable expectations for each
respondent’s own lifespan, the respondent can focus on the
health state without the distraction of an unrealistic time
horizon. In the current study, the ALE time horizon
allowed for a more accurate utility assessment, as indicated
by increased discrimination between mild and moderate
osteoarthritis health states. Furthermore, the ALE approach
does seem feasible as participants generally reported ALEs
within a reasonable range, and greater ALE tended to be
associated with younger current age (Table 2). Although
no time horizon is likely to be optimal in all utility studies,
current results suggest that researchers should think care-
fully about the choice of a time horizon, rather than
assuming that a 10-year time horizon is always appropriate.
The optimal time horizon for an individual study may be
selected based on clinical characteristics of the health
states, expected age of the target sample, and intended use
of the utility values. In some situations, it may be beneficial
to sacrifice comparability with other studies using the
10-year time horizon in favor of greater discrimination
among health states and relevance to the context of a
particular disease [52].
Regardless of which time horizon is used, it should be
clearly stated and justified in publications because it could
be a factor that influences results. Most articles reporting
TTO studies mention the time horizon, but few provide
justification for selecting a particular time horizon.
Among articles providing justification, some reported
choosing a time horizon to be consistent with the ALE
associated with the medical condition represented in the
health states [7, 19, 25, 30]. Others selected a 10-year
time horizon to be consistent with MVH study method-
ology [14, 15].
In sum, results suggest that the time horizon of the
utility assessment procedure could influence utility scores
and the degree to which respondents distinguish among
health states. Based on these findings, the time horizon
merits further investigation in future research with larger
samples and a wider range of health states. Furthermore, it
is recommended that researchers carefully consider the
selection of a time horizon when designing a TTO or SG
utility study and provide justification for the selected time
horizon when reporting study methods.
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Appendix A. Health states administered in this
study
Health State A: Mild osteoarthritis associated with elective
total hip arthroplasty.
1. You have slight hip pain and stiffness.
2. You don’t need a walking frame (Zimmer frame) or
walking stick, but you sometimes use a piece of
furniture to steady yourself.
3. You occasionally need to use over-the-counter pain
medication (such as paracetamol, aspirin, or
ibuprofen).
4. You have no night pain and you sleep well.
5. You are able to do all housework and chores if you
take your time.
6. Your social activity with family and friends is only
slightly decreased.
Health State B: Moderate osteoarthritis associated with
elective total hip arthroplasty.
1. You have moderate pain and stiffness upon exertion.
2. You need to use a walking stick to walk more than a
quarter of a mile (about 400 m).
3. You occasionally need to take prescription pain
medication.
4. You sometimes experience night pain that is relieved
by a position change and/or pain pills.
5. You can only do light housework or chores.
6. You socialise with family and friends, but more than
1 h is painful and tiring.
Health State C: Severe osteoarthritis associated with elec-
tive total hip arthroplasty.
1. You have almost constant pain and stiffness.
2. You must use a walking frame (Zimmer frame).
3. You regularly use prescription pain medication.
4. You sleep poorly at night.
5. You are unable to do most housework and/or chores.
6. You socialise with family and friends, but more than
30 min is painful and tiring.
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